TrialPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.

D Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.